March 14, 2025

Celonic Group Leverages Merck’s Breez™ Micro-Bioreactor Platform, Enabling Next-Generation Perfusion-Based Bioprocessing.

Celonic Group Leverages Merck’s Breez™ Micro-Bioreactor Platform, Enabling Next-Generation Perfusion-Based Bioprocessing.
  • Celonic Group leverages Merck’s Breez™ micro-bioreactor technology to optimize bioprocessing efficiency and scalability.
  • This technology integration supports Celonic’s efforts to enhance expertise in monoclonal antibody (mAb) development and manufacturing through advanced Next-Generation Technologies.
  • Celonic’s streamlined production, enabled by Merck’s technology, sets new standards in reducing the cost of goods per gram for biologics.

Basel, Switzerland, 12 March 2025 – Celonic Group, a Swiss-Based Quality contract development and manufacturing organization (CDMO), has announced that it is integrating Merck’s Breez™ micro-bioreactor platform into its process development. This addition will further enhance Celonic’s capabilities in monoclonal antibody (mAb) development and manufacturing by enabling highly efficient, scalable perfusion-based bioprocessing from early-stage development to large-scale manufacturing.

The Breez™ 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture system. By incorporating Breez™ into its process development, Celonic aims to accelerate upstream process optimization while reducing cost of goods per gram and increasing operational efficiency.

“This technology integration marks a significant milestone in our pursuit of innovative bioprocessing solutions,” said Samanta Cimitan Ph.D., CEO of Celonic Group. “By leveraging the Breez™ platform, we can enhance our ability to develop and manufacture biologics with the aim of increasing productivity, reducing the cost of goods per gram ultimately benefiting our clients and patients worldwide.”

About Celonic:

Celonic is a “Pure Play” Biologics Contract Development Manufacturing Organization (CDMO) with significant expertise in cell culture technologies, process development and manufacturing of recombinant proteins. Celonic’s roots trace back to 1982 as a spin-off of the Max Planck Institute in Germany. Today Celonic has a state-of-the-art Biologics Development and Innovation Center in Basel, Switzerland (Headquarters), and GMP manufacturing facilities in Heidelberg, Germany. This facility is equipped to handle complex biologics and bioprocessing technologies including fed-batch, N-1 perfusion and full perfusion production processes. At present, more than 500 highly qualified employees work at Celonic across the two locations.

Celonic Group Contact Details

Elisa Witt
Marketing and Communications Manager
Elisa.Witt@celonic.com
M: +41 76 588 67 59

Our latest News

discover more
DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

The aim of the project is to use special quantitative MRI to visualize early changes in the intervertebral disc and enable timely treatment. Ultrashort echo time (UTE) MRI opens up completely new approaches to preventive imaging that are difficult or impossible to achieve with conventional MRI methods. Full text in German below. DFG fördert Heidelberger […]

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Researchers from Heidelberg University’s Medical Faculty, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases (NCT) in Heidelberg have tested the use of targeted drugs in the initial treatment of newly diagnosed glioblastoma, an extremely aggressive brain tumor, in the multicenter study “NCT Neuro Master Match (N2M2)”. Of the five drugs […]

Global effort to sequence all life on Earth ramps up

Global effort to sequence all life on Earth ramps up

The Earth BioGenome Project is accelerating its efforts tenfold to sequence all life on Earth by 2035 Summary A global collaboration that includes experts at EMBL’s European Bioinformatics Institute (EMBL-EBI) has entered the second phase of its ambitious plan to sequence all 1.67 million known species on Earth by 2035.  The Earth BioGenome Project (EBP), a […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp